Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...

Uncertainty now dominates the COVID vaccine outlook after official recommendations were stripped for a variety of groups.

The FDA’s approval was based on a study of 11,400 people ages 12 and older that compared the new low-dose vaccine with ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on individuals who would be able to receive the vaccine. According to the ...

May 18 (UPI) --The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. The agency approved the vaccine only for people 65 and older ...

Pope Leo XIV’s inauguration Mass Sunday is filled with symbolism. Here’s what you need to know. Korea reports 12,284 new Covid-19 cases Tuesday Korea reports 10,368 new Covid-19 cases Friday Korea ...